StemCell Therapy

INTERVALE The Miranda Leavitt Diabetes Fund and the Conway Area Lions Club are hosting a Diabetes Awareness Event on Saturday, Nov. 16, from 10 a.m.-1 p.m. at the Miranda Diabetes Care Center, located at 3 N.H. Route 16 A in Intervale.

This free event will offer diabetes risk assessments, education on the link between diabetes and vision loss, blood glucose screening, blood pressure checks, plus information on diabetes prevention, nutrition advice and more.

Diabetes nurse practitioner Justine Fierman from the Miranda Diabetes Care Center and registered dietitian Brenda McKay from Memorial Hospital will be there to educate the community in the proper management of diabetes symptoms, and how many can decrease their risk in developing Type 2 Diabetes.

With November as National Diabetes Awareness Month, Conway Area Lions Club zone chair Linda Rafferty felt it was the right time to support an event around diabetes and vision loss.

The Conway Area Lions Club is a longtime supporter of the Miranda Leavitt Diabetes Fund and is known internationally for its work to improve health issues.

We are tackling tough problems like blindness and drug abuse as well as diabetes awareness and finding help and training for the deaf, disabled, underprivileged and the elderly. Whatever the community needs to make life better, were there to help, Rafferty said.

Rafferty said the event fits well into the Lions mission and supports a service project she personally is spearheading in her zone, which includes Lions Clubs in Laconia/Guilford, Moultonboro, Wolfeboro, Wakefield, Whittier, Meredith and Conway area.

I have chosen to spread diabetes awareness to all. This illness has affected some of my own family and friends and continues to strike many people. I was fortunate enough to meet with Brenda Leavitt and Justine Fierman from the Diabetes Care Center to work together on this project.

According to the American Diabetes Association, diabetes causes eye problems and may lead to blindness. People with diabetes do have a higher risk of blindness than people without diabetes. However, with regular checkups, most people with diabetes can keep minor vision problems minor.

Diabetic retinopathy is a general term for all disorders of the retina caused by diabetes. Huge strides have been made in the treatment of diabetic retinopathy. The sooner retinopathy is diagnosed, the more likely these treatments will be successful. The best results occur when sight is still normal. Several factors influence whether someone develops retinopathy:

Blood sugar control.

Blood pressure levels.

How long you have had diabetes.

People who keep their blood sugar levels closer to normal are less likely to have retinopathy or to have milder forms. This is why the November 16 event will be offering free blood glucose screenings and providing risk assessment information for developing diabetes.

But high blood glucose levels are just one of the risk factors of developing diabetes.

Factors such as age, weight, smoking, gender, family history, high blood pressure, activity level and ethnicity can all be indicators that diabetes could develop. Awareness and prevention efforts, such as weight loss, healthier diet choices, managing blood pressure and quitting smoking can all reduce the risk of developing Type 2 diabetes, and symptoms including vision loss.

Brenda Leavitt, founder of the Miranda Leavitt Diabetes Fund stated, We are gearing up for National Diabetes Month and the Miranda Leavitt Diabetes Fund, along with Conway Area Lions, is sponsoring this diabetes awareness event together. This disease is growing in our state and community, so the Diabetes Fund is putting together a series of screening, and education classes to follow. We are so pleased for the support from the Conway Area Lions Club and thank them for working with us on this event.

The U.S. Centers for Disease Control and Prevention reports that the number of Americans with diabetes continues to rise, with over 12 percent of the adult population estimated to have the disease, and more than a third of those aged 20 and over in the U.S. now thought to have prediabetes.

The Miranda Leavitt Diabetes Fund was founded in 2009 with a mission to provide resources, education and awareness for people with diabetes in the Mt. Washington Valley community. Miranda Leavitt passed away from complications of Type 1 Diabetes in 2007, and her parents, Rich and Brenda Leavitt, have tirelessly sought to raise funds and provide outreach around diabetes care and prevention.

The event takes place in the new location of the Miranda Diabetes Care Center in Intervale, NH. It is located at the intersection of Routes 16 and 16A. It is the practice of certified diabetes educator and nurse practitioner Justine Fierman. Fierman specializes in intensive diabetes management, insulin pump therapy, diabetes technologies, diabetes in pregnancy and continuous glucose monitoring.

For information on the Miranda Fund, go to Facebook page MLDFund. For more information on the Conway Area Lions, go to conwayarealions.org.

More:
Diabetes fund teams with Lions for awareness event - Conway Daily Sun

According to the CDC in the recent season, about 30% of adults in the hospital for the flu had diabetes.

The fact is people with diabetes, even if well-managed are at a higher risk of serious influenza complications.

According to the Director of Education and Patient Care at UHC, Brenda Conch these complications can result in hospitalization and sometimes even death.

"If they have diabetes specifically when they get the flu their diabetes is now out of control because that's what happens when an individual is ill, their glucose goes up," said Conch.

The reason those with diabetes or other chronic illnesses can get sicker from the flu is because their body is already fighting an illness.

"Your body is attending to that illness, so it doesn't really pay attention to something else coming at it," said Conch.

Conch says the flu shot is our best defense against the flu.

"Obviously the other ones is good hand hygiene and make certain you, but the best is through the flu vaccine," said Conch.

If someone with diabetes wants to get the influenza vaccine, it is recommended they must get the actual shot. Not the intranasal form because that can give you a minor case of the flu.

Obviously there are some misconceptions about the flu shot and how it works.

"Back in the old days it was a live virus, so there are people that still recall they got a shot a long time ago and they did get the flu with it. When you lived that it's hard to convince someone that is not how it is anymore. It does work, and it does work against flu we're immunizing for," said Conch.

Conch says there is an exception to every rule, but pretty much everyone needs to get the flu shot. The exception being infants or if your doctor tells you otherwise.

In addition, after an individual receives the flu shot it takes 14 days to take full effect.

See the article here:
Those with Diabetes are at greater risk for the flu and flu complications - WDTV

How the changes impacted her life and health

The pounds dropped off of Snita, losing three stone to weigh in now at eight stone. To top it off, Snita received her blood test results shortly before her 50th birthday which revealed she was no longer within the diabetic range.

Snita now considers herself a running addict and regularly runs 5ks, 10ks and half marathons. Later this year, she will take part in the iconic Simplyhealth Great South Run, part of a series of mass participation running events which has partnered with Diabetes UK, to encourage more people to become more active.

Snita is effusive in her praise for the impact running has had on her life and recently delivered a talk, with the help of Diabetes UK, on the life-changing effect it can have on other people living with diabetes.

The impact running has had on my life has been huge. If I hadnt joined my running club and got the support Ive had from my coach and the rest of the group I wouldnt have kept it up.

Running has really helped my diabetes by getting me fitter and forcing me to address my diet, which together have helped me diabetes enter into remission.

Snita has been running medication-free for 19 months now and as well as running the Simplyhealth Great South Run later this year, has also recently completed half marathons in London, Liverpool and Dublin.

She feels happier, fitter and healthier now than she has since her 20s and is determined to continue challenging herself. Its been a real journey which Im still on and I feel like a changed person.

I have so much energy and do so much more in a day than I ever did before. Its been truly life-changing.

More here:
Type 2 diabetes: Women puts her diabetes into remission by doing this activity - Express

Named after pioneering poet and activist Audre Lorde, Spelman College plans to establish a chair in queer studies, the first for a Historically Black College or University (HBCU), The Root reports. The position was supported by a $2 million donation from philanthropist Jon Stryker. In a statement issued to Forbes, Stryker states his donation helps to further students' education on LGBTQ rights.

"The more that people understand queer history and LGBTQ issues, the more likely they are to accept and support the LGBTQ community," Stryker said. "By empowering and educating the next generation, we can help make a future where LGBTQ people have full and equal protections under the law."

Mary Schmidt Campbell, Spelman's president, discussed the significance behind this new department.

A chaired professorship in Queer Studies enables the College to build on one of its strengths and that is the Spelmans educational inclusiveness, spearheaded by the Womens Research and Resource Center under the stellar direction of Dr. Beverly Guy-Sheftall," Campbell said. "Spelmans Womens Center has been and continues to be a pioneering leader in advancing scholarship in the area of Queer Studies. Jon Strykers generous contribution to further his commitment to LGBTQ inclusion and education will allow Spelman students to deepen their understanding around the study of sexuality and gender. We are honored to name the chair after the literary luminary and fierce activist, Audre Lorde.

Spelman College announces a $2M match from philanthropist Jon Stryker to establish an Endowed Queer Studies Chair named after poet and activist Audre Lorde. The professorship is the first-ever chair of its kind at an HBCU. https://t.co/nb7FVHEOal pic.twitter.com/fBIEfPFBdm

Spelman College (@SpelmanCollege) October 29, 2019

The news arrives two years after Spelman announced the admission of transgender women students, beginning in 2018."In adopting this admissions policy, Spelman continues its fervent belief in the power of the Spelman Sisterhood," Campbell said in a letter. "Students who choose Spelman come to our campus prepared to participate in a women's college that is academically and intellectually rigorous, and affirms its core mission as the education and development of high-achieving black women."

More:
'Yo! MTV Raps' Doctor Dre Discusses Living With Type 2 Diabetes And Partial Vision Loss - Vibe

In a previous related study conducted with a team from the University of Gothenburg in Sweden researchers also found that dietary fibres from barley kernel generates an increase of the gut bacteria Prevotella copri, which have a direct regulatory effect on blood sugar levels and help decrease the proportion of a type of gut bacteria that is considered unhealthy.

According to Diabetes UK, certain breakfast cereals can pose hidden risks for people with type 2 diabetes, as they contain free sugars. Free sugar is any sugar added to a food. Extra sugar means extra calories and eating too many calories can lead to obesity - a major risk factor associated with type 2 diabetes.

Breakfast cereals rich in free sugars include granola and cereal clusters, which, despite appearing healthy, are often full of free sugars and unhealthy fat.

As Diabetes Uk explained: When buying cereal, the best thing to do is look at the 'front of pack' label, and try to go for cereal with as many green lights as possible. But also check the ingredients list, some newer versions of granola simple have nuts added in.

See the original post:
Type 2 diabetes: Eating this cereal for breakfast could lower blood sugar - Express

ARLINGTON, Va., Oct. 30, 2019 /PRNewswire/ -- The American Diabetes Association (ADA) strongly supports the introduction of the Insulin Price Reduction Act in the United States House of Representatives. The ADA thanks Congressional Diabetes Caucus Co-Chairs Representative Diana DeGette (D-CO) and Representative Tom Reed (R-NY) for their leadership in introducing the House version of this legislation, which will lower the cost of insulin for many Americans who rely on it to stay alive. The Insulin Price Reduction Act was first introduced in the United States Senate on July 22, 2019.

For more than 7.4 million Americans, including all individuals with type 1 diabetes, insulin is a life-sustaining medication for which there is no substitute. Ballooning costs have put lifesaving insulin out of reach for an increasing number of Americans. Between 2002 and 2013, the average price of insulin nearly tripled. A 2018 ADA survey showed that individuals with diabetes who face high out-of-pocket costs are forced to make decisions about their insulin regimen that can have damaging consequences on their health. Many individuals with diabetes ration or forego insulin doses to reduce costs.

"Insulin is a matter of life and death," said LaShawn McIver, MD, MPH, Senior Vice President of Government Affairs and Advocacy. "For the many Americans who cannot afford their insulin, the consequences can be dire, including serious complications, such as cardiovascular disease, blindness, kidney disease, amputation, and even death. The American Diabetes Association applauds Representatives DeGette and Reed for their leadership in addressing this urgent issue. We urge all members of the House of Representatives to support this critical legislation and advance it through the legislative process."

The Insulin Price Reduction Act seeks to address the skyrocketing cost of insulin by encouraging insulin manufacturers to reduce the list price of all insulin products to their 2006 list price. Importantly, these lower-priced products would not be subject to health plan deductibles and would not be placed on less favorable formulary tiers. Rolling back list prices for insulin products by over a decade will make insulin more accessible for many Americans, both insured and uninsured.

The ADA continues to work diligently on the critical issue of insulin affordability. In 2016, the ADA's Board of Directors released a resolution calling on all entities in the insulin supply chain to increase transparency in insulin pricing and to ensure that no one living with diabetes is denied affordable access to insulin. The resolution also called on Congress to hold hearings with all entities in the insulin supply chain to help identify the reasons for the dramatic increases in insulin prices and to take action to ensure that all people who use insulin have affordable access to the insulin they need. The ADA's Make Insulin Affordable petition has achieved more than 487,000 signatures to date. In 2017, the ADA's Board of Directors convened an Insulin Access and Affordability Working Group, and the Working Group's findings were detailed in a white paper published in 2018 in the journal Diabetes Care. The ADA subsequently issued a public policy statement providing detailed recommendations to lawmakers. The ADA has also testified at multiple congressional hearings in 2018 and 2019 focused on the high cost of insulin. Resources are available through the ADA's call center at 1-800-DIABETES, and at InsulinHelp.org.

About the American Diabetes AssociationEvery day more than 4,000 people are newly diagnosed with diabetes in America. Nearly 115 million Americans have diabetes or prediabetes and are striving to manage their lives while living with the disease. The American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For nearly 80 years the ADA has been driving discovery and research to treat, manage and prevent diabetes, while working relentlessly for a cure. We help people with diabetes thrive by fighting for their rights and developing programs, advocacy and education designed to improve their quality of life. Diabetes has brought us together. What we do next will make us Connected for Life. To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (1-800-342-2383). Join the fight with us on Facebook (American Diabetes Association), Twitter (@AmDiabetesAssn) and Instagram (@AmDiabetesAssn).

Contact: Alex Day, 703-253-4843press@diabetes.org

See original here:
The American Diabetes Association Applauds the Insulin Price Reduction Act, Introduced Yesterday by the House Diabetes Caucus - The Breeze

(StatePoint) Two in five Medicare patients with diabetes (40.9 percent) reach the Part D coverage gap, and are responsible for the full cost of their prescription drugs.(1)To help ease this financial burden, Eli Lilly and Company offers several solutions, including insulins with a lower list price.

People with diabetes will need to make important decisions for healthcare coverage during the Medicare open enrollment period (October 15 to December 7, 2019). To help ensure treatments are affordable, its important to consider the following when choosing a Medicare coverage plan:

Make a list of important priorities including cost, coverage and network that your plan must have based on your individual health needs.

A checklist can help guide important conversations when choosing a plan. Lillys checklist can help identify different cost, coverage and network considerations specifically for people with diabetes.

When considering which plan to choose, Lillys Plan Guide can help identify which Medicare Part D plans cover the lower priced insulin in each state.

The transition to Medicare for people with diabetes can be difficult and there are many factors, such as cost, that go into making a coverage decision. Were working to ease the financial burden for the growing number of people with diabetes who are in the coverage gap phase of their plan, said Tony Ezell, vice president, U.S. Connected Care and Insulins, Lilly. The goal is that Lillys solutions will help people with diabetes access affordable insulin until long-term, systemic changes are made to the U.S. healthcare system.

Visit InsulinAffordability.com or call the Lilly Diabetes Solution Center to learn more about the solutions available that may help people with diabetes significantly decrease the amount they pay for Lilly insulin. Helpline representatives are available at (833) 808-1234 from 9 a.m. to 8 p.m. ET Monday through Friday.

PP-SP-US-0110 10/2019 (c)Lilly USA, LLC 2019. All rights reserved.

(1) American Diabetes Association. The Impact of Medicare Part D on the proportion of Out-of-Pocket Prescription Drug Costs Among Older Adults With Diabetes. Available at: https://care.diabetesjournals.org/content/40/4/502.long. Accessed October 1, 2019.

Follow this link:
Medicare and Diabetes: A Few Things to Know - Coronado Eagle and Journal

Additionally, rates of infection, mortality and readmission are 4x, 1.5x and 1.4x greater, respectively.

The question is, are we as a healthcare community doing everything we can to improve these outcomes? Are we paying enough attention to the unique needs of patients with diabetes?

The results of recent nationwide survey indicate we need to do better, and with the shift from volume to value, I would say the question becomes, can we afford not to?

Download the complete survey results here.

The truth is, managing diabetes within our inpatient populations is strife with challenges. This is a large-scale issue and the numbers are growing.

On average, one of every three hospitalized patients -- the majority with diabetes -- requires insulin to control blood glucose during their stay, a medication that although widely prescribed and absolutely necessary is inherently dangerous. Fifty percent of all medication errors involve insulin, including one-third of all fatal medication errors. Insulin is considered a high-alert medication because it has the potential to cause significant patient harm if misused.

Certainly hospitals and health systems face other patient safety challenges, but very few have as substantial an impact on both clinical and financial outcomes. Insulin therapy, whether intravenous or subcutaneous, is both complex and difficult to manage.

When insulin therapy lacks standardization and best practices are not the norm, poorly controlled blood glucose prevails, which can lead to coma, stroke, sepsis, cardiac arrest . . . even death. A recent study by AdventHealth Orlando showed that hospitalized patients who experience severe hypoglycemia (abnormally low blood glucose) incur $10,405 of excess cost per stay and a 61.5% higher readmission rate.

This toll is largely avoidable, but only if hospitals and health systems prioritize glycemic management. The results of this survey underscore there is vast room for improvement.

Download the complete survey results here.

Some of the findings that strike me as concerning include:

The good news is, improving the care of hospitalized patients with diabetes and achieving best practices in glycemic management are attainable goals, especially with the aid of purpose-built technologies such as the eGlycemic Management System.

You are welcome to arrange a complimentary consultation with a Glytec clinical executive to discuss your glycemic management needs and goals. Click here.

Dr. Rhinehart is a diabetologist and Chief Medical Officer of Glytec. He was the first U.S. physician board certified in advanced diabetes management (BC-ADM).

Read this article:
Survey reveals better care needed for hospitalized patients with diabetes - HealthLeaders Media

For kids with food allergies, dietary restrictions or Type I diabetes, Halloween trick-or-treating can put kids at risk for serious health issues.

Candies made with peanuts, eggs, and wheat and dairy products may expose children to food allergens, and sweet treats elevate blood sugar levels.

"There are ways to make (Halloween) fun even though they can't eat all the candy they collect," said Shelby Shelby, a registered dietitian with Owensboro Health.

She suggested families may want to consider inviting the "Switch Witch" to visit Halloween night. Kids lay out all the candy they've collected, and the Switch Witch comes while they sleep something like the tooth fairy to exchange the candy for money, movie tickets, trips to the zoo, gift cards or toys.

Somer Wilhite, manager of marketing at OH, has kids ages 6 and 10.

"We've already been trick-or-treating twice this week," Wilhite said.

She pays her kids $1 per 20 pieces of candy they hand over. Then, she gives away the treats. Nursing homes, hospitals and homeless shelters usually appreciate a little extra candy, she said.

Shelby participates in the Teal Pumpkin Project, a national effort to make Halloween safe and happy for all kids. Homeowners paint a pumpkin teal and put it on the front porch to indicate they give nonfood treats, such as boxes of crayons, bubbles, whistles, glow sticks and temporary tattoos.

"The project gives the same experience to kids who can't have candy. Having those options opens it up to all children to have fun," Shelby said.

The Teal Pumpkin Project has a national map of participating homes.

When Shelby finds trick-or-treaters at her door, she asks if any of the goblins have allergies or other reasons for needing a nonfood treat. She has two bowls ready one with candy and one with trinkets.

She often finds kids with no dietary restrictions are just as interested in a toy because they've gathered so much candy already.

Shelby goes to a party store to buy bags of trinkets. In many ways, they are better to hand out to everyone dietary restrictions or not, she said. Candy doesn't keep year to year. Plastic trinkets do.

The same is true for the kids. Candy gets gobbled quickly. Toys, crayons and other nonfood treats last much longer.

For families that deal with Type I diabetes, Shelby shared many tips for trick-or-treating.

"Plan ahead first and foremost," she said. "Sit down with your child and make a plan for Halloween night and school parties."

The joint plan needs to be shared with anyone the child comes in contact with so friends and family can help support the plan.

Children with diabetes should have a healthy dinner with protein before treat-or-treating because it can help buffer blood sugars.

Shelby recommends knowing the carbohydrate counts of common candies. Parents can find an online list at beyondtype1.org.

Children with diabetes or food allegies should wear a medical ID bracelet when they trick-or-treat with friends.

"Make a new tradition," Shelby said. "Make lower carbohydrate Halloween treats and have a party at home rather than trick-or-treating."

Link:
Halloween is tricky time for kids with food allergies, diabetes - Grand Haven Tribune

HAMILTON, Ontario, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Reliq Health Technologies Inc. (TSXV:RHT or OTCQB:RQHTF) (Reliq or the Company), a technology company focused on developing innovative mobile health (mHealth) and telemedicine solutions for Community Healthcare, today announced that it has partnered with leading US Diabetes Care company Smart Meter LLC. (Tampa, FL) to provide Reliqs iUGO CARE Remote Patient Monitoring (RPM) and Chronic Care Management (CCM) solutions to patients coping with diabetes and other chronic conditions.

The iGlucose blood glucose meter is compact, portable, user friendly and cellular-enabled, so its an excellent fit for rural and remote diabetes patients who may not have conventional internet access, as well as for active diabetics who need a glucose meter that they can take with them wherever they go, said Dr. Lisa Crossley, CEO of Reliq Health Technologies, Inc. Integrating with the iGlucose meter allows us to offer our clients innovative new options for managing diabetes in the community. The partnership with Smart Meter also fits our new Call Centers business model. Reliqs Call Center in Port St Lucie, FL is focused on implementation of our iUGO CARE Remote Patient Monitoring (RPM) and Chronic Care Management (CCM) solution with patients, physicians and payors. The resources of the Call Center will facilitate enrollment and support patients and their healthcare providers. Not only will the Call Center offer paid support services to our clients, we have also secured commitments from partners, including Smart Meter, to utilize our contract outreach and engagement services. As a result, the Call Center will be self-funding and profitable from day one.

Were excited to partner with Reliq Health to offer their advanced technology platform to our enterprise clients, said Mr. Brahim Zabeli, CEO of Smart Meter LLC. Smart Meter has relationships with clinicians and disease management companies, and we look forward to helping these providers reduce costs and improve patient care through our partnership with Reliq. Combining our iGlucose meter and cost-effective test strips, and Reliqs iUGO CARE platform to support caregiver workflows, automatically collect key patient health data and connect residents to physicians through virtual visits, will create new revenue models for residential care, increase profits and enhance patient and family satisfaction. We are also pleased to be able to leverage Reliqs Call Center for outreach and engagement to expand our client base.

About Smart MeterSmart Meter, LLC is the innovator of iGlucose; a simple, convenient and affordable solution addressing todays challenges in the monitoring and management of diabetes. The game-changer is cellular technology, which allows patients to just test, letting iGlucose seamlessly share patient data. Providers, in real time, now receive comprehensive, powerful, reliable data, allowing for individualized care and targeted population health management. iGlucose is a simpler, quicker path to improve outcomes, lower costs and access new sources of reimbursement through remote patient monitoring. To find out more about how iGlucose is simply doing the unimaginable through Better Data, Better Care, Better Outcomes, visit http://www.iglucose.com.

About Reliq HealthReliq Health Technologies is a healthcare technology company that specializes in developing innovative software solutions for the Community Care market. Reliqs powerful iUGO CARE platform supports care coordination and community-based healthcare. The iUGO CARE platform integrates wearables, sensors, voice technology and intuitive mobile apps and desktop user interfaces for patients, clinicians and healthcare administrators. iUGO CARE allows complex patients to receive high quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery. iUGO CARE provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits. Reliq Health Technologies trades on the TSX Venture under the symbol RHT and on the OTCQB as RQHTF.

ON BEHALF OF THE BOARDDr. Lisa CrossleyCEO and Director

For further information please contact:Investor Relations at ir@reliqhealth.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking InformationCertain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking statements".

We caution you that such "forward-looking statements" involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.

Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including technology development, anticipated revenues, projected size of market, and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.

Reliq Health Technologies Inc. (the "Company") does not intend and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, technology development and marketing activities, the Company's historical experience with technology development, uninsured risks. Actual results may differ materially from those expressed or implied by such forward-looking statements.

SOURCE: Reliq Health Technologies Inc.

#406A 175 Longwood Rd SHamilton, ON, L8P 0A1Phone: (888) 869-1362Fax: (647) 317-1929

Continue reading here:
Reliq Health Technologies, Inc. Partners with Leading US Diabetes Care Company to Deliver RPM/CCM Solutions - GlobeNewswire

NEW YORK CITYLife insurance company John Hancock is teaming up with VerilyLife Sciences to offer a life insurance solution anddigital wellness program to help people with diabetes manage and improve their condition.

The new product, John Hancock Aspire, isa unique collaboration between the Boston-based life insurer and Verily, the healthcare division of Google parent company Alphabet,and will leverage the capabilities of Onduo, a virtual diabetes clinic.

Onduo is ajoint venture between Verily and drugmaker Sanofi.that was spun off in 2016 and now partners with health insurers like Blue Cross Blue Shield to provide chronic care management toplan members with diabetes. Onduo also is collaborating with Walgreens on a virtual diabetes and medication adherence solution for the company's employees.

Like this story? Subscribe to FierceHealthcare!

The healthcare sector remains in flux as policy, regulation, technology and trends shape the market. FierceHealthcare subscribers rely on our suite of newsletters as their must-read source for the latest news, analysis and data impacting their world. Sign up today to get healthcare news and updates delivered to your inbox and read on the go.

RELATED:Blue Cross Blue Shield Association partners with Google affiliate for diabetes care pilot

Through the collaboration with Verily and Onduo, John Hancock is offering consumers living withdiabetes a life insurance plan combined witha technology-enabled wellness program that provides coaching, clinical support, education and rewards designed to help manage and improve their health. Plan members have the potential to save up to 25% on their premiums, according to the company.

Qualifying John Hancock Aspire customers with Type 2 diabetes will get access toOnduo's virtual clinic, which includes blood glucose monitoring devices paired with the Onduo app, and will be connected to Onduo's virtual care team forpersonalized guidance and support.

During an event in Manhattan Monday to announce the new partnership, Andy Conrad, Verily's CEO, said it was a "daring" collaboration that presented an opportunity to scale up Onduo's virtual diabetes clinic.

"Through this initiative, Verily and John Hancock are pushing the envelope on the role life insurance can play in both providing financial security and helping people live longer, healthier lives," Conrad said.

"This is a great opportunity to do this at scale and in a clever, thoughtful and different way," he said.

Brooks Tingle, president and CEO of John Hancock Insurance, said his industry hasn't traditionally served people living with diabetes well.

"We're actually among the most uniquely positioned to help improve their health outcomes because our customer relationships often last a lifetime," he said.

RELATED:Walgreens and Verily announce partnerships for diabetes, medication adherence

Tingle told FierceHealthcare the company saw an opportunity to work with a leading technology company to leverage a personalized approach to disease management and make life insurance more personalized and engaging.

"There are wonderful solutions out there and wanted to take those andplug them into alife insurance policy. We're trying to make life insurance as much about living as dying," he said.

"The organizations that will have the greatest impact on healthcare will be companies like Google," Tingle said. "These companies are making significantinvestments to use technology and analytics to improve health outcomes."

Google's work with Verily was driven by a desire to do "world-changing projects," Conrad said. "In areas like healthcare, we wanted to change the paradigm from an episodic perspective to prevention." The collaboration with John Hancock fits into that mission, he noted.

The two companies could potentially expand the partnership to other chronic diseases such as hypertension or depression, Conrad said.

For John Hancock Insurance, the more than30 million Americans living with diabetes represent a sizable market opportunity. Half of those consumers either don't have enough life insurance or don't have any life insurance coverage at all, according to data from the Centers for Disease Control and Prevention.

Diabetes remains the seventh leading cause of death inthe U.S., with 1.5 million Americans diagnosed every year, according to the American Diabetes Association.

Former emergency medicine physician Joshua Riff, M.D., now CEO of Onduo, said he joined the Verily-Sanofi joint venture because he saw firsthand the toll of chronic disease on patients.

RELATED:Alphabet's Verily collaborating with Atrius Health, Palo Alto VA on population health projects

The majority of patients he saw in the emergency roomhad some form of chronic disease or complications due to their disease, he said. "Why are they coming to see me? When I would ask, I would hear the same story. Patients would say'I have a hard time getting to my doctor.''I only see my doctor a few times a year, but I live with this disease 365 days a year andI have no support or guidance.'"

Onduo's platform was developed to transform how chronic care is delivered, Riff said, with a focus on health monitoring and tracking, personalized guidance andaccess to care teams. "It's designed to support people where they are and on their terms," he said.

"It's rare to be a part of something where all the incentives are aligned," Jessica Mega, M.D., chief medical officer at Verily, told FierceHealthcare. She noted that the program provides incentives and rewards that support consumers' financial health and physical health and well-being. And Onduo's technology platform uses data to tailor guidance and support to each patient, she said.

"The fact that the medical community is now embracing this is important. We're empowering patients to help them make healthier choices," she said.

Verily, originally Google Life Sciences, once part of Google X,spun outin 2015 to lead Alphabets healthcare and life sciences research. The company has beenquietly expanding its footprint in the world of healthcare and collaborating with health systems and other providerson initiatives to tackle major healthchallenges.

The company recently announced it was teaming up with Atrius Health and the Palo Alto Veterans Affairs healthcare system to improve patient outcomes through population health initiatives.

The rest is here:
Verily, John Hancock collaborating on life insurance solution that offers virtual diabetes management - FierceHealthcare

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced presentation of real-world data from pediatric users of the t:slim X2 insulin pump with Basal-IQ predictive low-glucose suspend technology at the 45th annual conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD). Data from 2,696 users under the age of 18 years old showed an overall rate of hypoglycemia of only 0.9 percent when using Basal-IQ technology. A subgroup of users with at least 21 days of sensor-augmented pump data prior to use of Basal-IQ technology demonstrated a 31 percent reduction in hypoglycemia following introduction of the feature (n=491).

Data Highlights

The study included de-identified real-world data uploaded to Tandems t:connect web application between August 31, 2018 and March 14, 2019, which was retrospectively analyzed to assess hypoglycemia outcomes.

Overall Group (n=2,696) The overall rate of hypoglycemia (defined as percent median time spent with sensor readings <70 mg/dL or 3.9 mmol/L) for this group was 0.9 percent. Algorithm-enabled insulin suspensions occurred on average 4.9 times per day for an average 15.5 minutes per suspension.

Subgroup (n=491) Pre-post analysis demonstrated median time spent <70 mg/dL or 3.9 mmol/L decreased from 1.6 to 1.1 percent upon introduction of Basal-IQ technology (p = <0.001), representing a 31 percent reduction in hypoglycemia. Sensor time-in-range (defined as 70-180 mg/dL or 3.9-10.0 mmol/L) remained steady between pre- and post-Basal-IQ technology use, however, there was a significant decrease in sensor glucose values greater than 300 mg/dL or 16.7 mmol/L (p=0.007).

About the t:slim X2 Insulin Pump with Basal-IQ Technology

The simple-to-use t:slim X2 insulin pump with Basal-IQ predictive low glucose suspend technology uses glucose values from an integrated Dexcom G6 continuous glucose monitor to predict and help prevent lows with zero fingersticks*. The t:slim X2 insulin pump includes advanced features like a large color touchscreen, rechargeable battery, Bluetooth wireless technology, USB connectivity and watertight construction (IPX7)1. It is capable of remote software updates using a personal computer, offering the potential for in-warranty users to access new features as they meet necessary regulatory requirements2. The t:slim X2 insulin pump is up to 38 percent smaller than other insulin pumps and holds up to 300 units of insulin.3

Launch of the t:slim X2 insulin pump with Basal-IQ technology has begun in select international geographies. It is currently available on new t:slim X2 insulin pumps and as a software update to all in-warranty t:slim X2 insulin pump users in the United Kingdom, Sweden, Denmark, Spain, Italy, the Czech Republic, and South Africa.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandems flagship product, the t:slim X2 insulin pump, is capable of remote software updates using a personal computer and features integrated continuous glucose monitoring. Tandem is based in San Diego, California.

Tandem Diabetes Care, t:connect, and Basal-IQ are registered trademarks, and t:slim X2 is a trademark of Tandem Diabetes Care, Inc. Dexcom and Dexcom G6 are registered trademarks of Dexcom, Inc. The Bluetooth wordmark is a registered trademark owned by Bluetooth SIG, Inc. and any use of such mark by Tandem Diabetes Care, Inc. is under license. All other third-party marks are the property of their respective owners.

Important Safety Information for the t:slim X2 Insulin Pump with Basal-IQ Technology

Federal (USA) law restricts this device to sale by or on the order of a physician. The t:slim X2 insulin pump with Basal-IQ technology (the System) consists of the t:slim X2 insulin pump, which contains Basal-IQ technology, and a compatible CGM. CGM sold separately. The t:slim X2 insulin pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The t:slim X2 insulin pump can be used solely for continuous insulin delivery and as part of the System. When the System is used with a compatible iCGM, Basal-IQ technology can be used to suspend insulin delivery based on CGM sensor readings. The System is indicated for use in individuals 6 years of age and greater. The System is intended for single patient use and requires a prescription. The System is indicated for use with NovoLog/NovoRapid or Humalog U-100 insulin. The System is not approved for use in pregnant women, persons on dialysis, or critically ill patients. The pump is not intended for anyone unable or unwilling to: use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see their healthcare provider regularly. The user must also have adequate vision and/or hearing to recognize all functions of the pump, including alerts. For detailed indications for use and safety information, visit tandemdiabetes.com/safetyinfo.

Forward Looking Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements relate to, among other things, the ability of the t:slim X2 pump to provide remote feature updates, the timing and outcome of regulatory approvals for new product features and updates, and the ability of our products to improve customer satisfaction and clinical outcomes. These statements are subject to numerous risks and uncertainties, including the risks that technical problems may prevent or delay remote software updates, regulatory agencies may fail to approve new product features or updates on our expected timeframe or at all, and the level of customer satisfaction from the use of our products and features may be different from what we expect, as well as other risks identified in Tandems most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, respectively, and other documents we file with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors.

* If glucose alerts and CGM readings do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions. Dexcom G6 CGM sold separately.

1 Tested to a depth of 3 feet for 30 minutes2 Additional feature updates are not currently available for the t:slim X2 insulin pump with Basal-IQ technology and are subject to future FDA approvals. A prescription and additional training may be required to access certain future software updates.3 38 percent smaller than MiniMed 630G and 670G and at least 28 percent smaller than MiniMed 530G, Animas Vibe and Omnipod System. Data on file, Tandem Diabetes Care.

Read this article:
Tandem Diabetes Care Presents Positive Real-World Data from Pediatric Users of t:slim X2 Insulin Pump with Basal-IQ Technology at International...

Green advocacy groups, mostly based in Europe, are the single biggest impediment to sustainable agriculture, said GLP executive director Jon Entine in an interview with Marcel Bruins, editorial director of European Seed magazine and website.

CRISPR and other gene-editing and New Breeding Techniques are fast being adopted around the world, although many environmental activist groups are doing their best to frighten the public and intimidate legislators into erecting insurmountable regulatory barriers. Theyve been largely successful in Europe, which is blocking gene-edited crops under legislation passed in the pre-CRISPR era in 2001, Entine said, but the rest of the world is more open to the innovations.

Entine was interviewed in mid-October at the annual Euroseeds Congress 2019, held in Stockholm.

The GLP founder raised a range of challenges facing agriculture in the face of what can only be called a determined anti-technology faction. Africa appears to be emerging as a central battleground. Europe has strong historical trade and cultural ties to the continent. It has long used those connections to push its anti-GMO policies. Africa is now rebelling, Entine noted, and is pursuing biotechnology innovation led by African scientists, particularly focusing on animal biotech, in an attempt to shed Europes yoke.

Its an uphill battle for Europe and Africa, Entine noted. Activist groups, mostly from European nations, are going door-to-door, telling Africans deliberate falsehoods about biotechnology, claiming that genetically engineered crops cause cancer and sterility.

Entine went on to offer a communications strategy to give the science a chance, so crop biotechnology has an opportunity to succeed on its merits, without being tangled in Europes ideological web.

Jon Entine is the founder and executive director of the Genetic Literacy Project. Twitter: @jonentine.

Read more:
Video: 'Blood on their hands'Greens' resistance to biotechnology blocks sustainable agriculture, climate change innovation, says GLP's Jon Entine -...

In attendance at the Park Hyatt Hotel in Midtown Manhattan, were approximately 140 guests, predominately from the US, but also from across Europe, the Middle East, Asia as well as Australia. Partners Capital's client base of investment professionals, institutional clients and family offices were all represented. This included investment committee members from New York University School of Law, the Los Angeles Museum of Contemporary Art, Singapore educational endowments and INSEAD Business School.

The afternoon started with Stan Miranda, Chief Executive Officer of Partners Capital, describing the overarching theme of the Client Workshop being de-globalization, with four underlying sub-themes - geopolitics, China, biotechnology and impact investing. "While Globalization has been a strong force in the past, lifting people out of poverty and bringing the world closer together, there are serious headwinds. Given these headwinds, we face a question of whether investors should concentrate their investments more domestically or seek opportunities out of new economic alliances that are likely to form?" The afternoon provided arguments on multiple sides.

Internal speakers were joined by three experts:

Matthew Gertken, Geopolitical Strategist at BCA Researchspoke on geopolitics' impact on investment strategy going forward. BCA research concludes that the US will be in at least a decade-long economic "cold war" with China. Any trade deals between now and Trump's re-election will be temporary stop-gaps distracting investors from the real changes in the form of deeper alliances between China and its historical and new allies; and between the US and its historical allies.

Jason Tan, Chief Investment Officer from Jeneration Capitallaid out the facts surrounding the technology arms race between China and the US, highlighting the very different strategies Chinese tech leaders are following versus US tech leaders. These companies initially start with one online business and subsequently expand into additional segments (e.g., content & media, social & messaging, mobile payments), funding start-ups to create new innovations so they do not have to themselves. The integrated ecosystem approach is highlighted by the fact that China is home to a disproportionate number of the "super" unicorns ($15B+ valued companies).

Behzad Aghazadeh, Managing Partner at Avoro Capitalspoke on the future biotechnology breakthroughs saying that "today we are benefitting from the groundwork of decades of research that can now be widely applied to medicine.breakthroughs in cancer are accelerating as we continue to see advances in treatments for previously uncurable indications. Today there are 16,000 ongoing pipeline projects, up from 6,000 in 2001, which provides a strong platform of ongoing innovation in the sector".Stan Miranda added his own comments on investing in the public biotech sector - "There are 1,200 public biotech companies today, only 5% of which have revenue and 75% have not yet reached phase III drug trials. By investing with firms like Avoro, we expect to see venture capital like returns from this liquid public sector of the public equity markets."

Partners Capital presentations included two four-person panel sessions featuring the Partners Capital CIO's and Asset Class Heads, addressing Client Portfolio Strategy Choices and Asset Class Strategies going forward, respectively.

- Will Fox, Partner, Head of North America, Boston - spoke on the right illiquidity budget

- John Collis, Partner, Head of Europe, London spoke on tactical asset allocation

- Elizabeth Trotta, Managing Director, New York covered our recession playbook

- David Shushan, Partner, Boston discussed technology sector over-weights

- Alex Band, Managing Director, Head of Public Equities, Boston

- Rich Scarinci, Partner, Absolute Return & Credit, Boston

- Suzanne Streeter, Partner, Head of Private Markets, Boston

- Emma Bewley, Principal, Private Debt, London

The audience responded most to Elizabeth Trotta's run-through of the "Partners Capital Recession Playbook", which is already in place in most client portfolios. But the key message of the internal presentations was how Partners Capital believes that a highly diversified, risk-managed multi-asset class portfolio is the best long term defense against an economic downturn.

The afternoon's final session, Impact Investing, featured a short video of Sir Ronald Cohen, filmed specifically for the event, addressing the importance of social impact investing and why investors should be focusing not only on risk and return but also on optimizing the impact of their investments on society and the environment. Euan Finlay, Partner and Chair of Partners Capital's Responsible Investing Committee, then went on to discuss the firm's responsible investing framework for implementing and reporting on responsible investing in client portfolios.

Paul Dimitruk, Chairman of Partners Capital, closed the day focusing on the firm's desire to be not just an advisor, but a "thought-partner" on each client's investment journey. He implored each client to continue to challenge and push Partners Capital to be the best it can be. "Our mission is to do go beyond just asset allocation and manager selection, but to help discern where risk and return are, and where value is created or destroyed."

About Partners Capital

Founded in 2001, Partners Capital is a wholly independent Outsourced Investment Office (OCIO) primarily serving sophisticated institutions and senior investment professionals inEurope,North AmericaandAsia. With offices inBoston,New York,San Francisco, London, Singapore and Paris, the firm is one of the few truly global OCIOs, employing 175 people worldwide and covering all major asset classes. The firm oversees assets of more than$27 billion. Its institutional clients include a number of Oxford and Cambridge Colleges,Eton College, INSEAD business school, the Research Foundation for theState of New York'sUniversity System, the Royal Academy of Arts, Milton Academy, the Hong Kong Cancer Fund and the Cancer Research Institute. Additional information on Partners Capital may be found athttp://www.partners-cap.com.

Photo: https://mma.prnewswire.com/media/1019263/Partners_Capital_AIW_Image.jpg Logo: https://mma.prnewswire.com/media/817400/Partners_Capital_Logo.jpg

SOURCE Partners Capital

Home

See the rest here:
Partners Capital Shines the Spotlight on Geopolitics, China, Biotechnology and Impact Investing at Its Fourth Annual Investor Workshop - PRNewswire

Biotechnology Market will expand at +9.9% CAGR to hit $775 Billion by 2025

Biotechnology For example, growth in this area is expected to accelerate as the proliferation of conditions such as hepatitis B disease and other problems increases. The growing population in the United States, China, and India is expected to increase the importance of these products due to growing interest in livelihood and horticultural items such as wheat, rice, sugar cane, and soybeans. In addition, factors such as water shortages, low yields, insect attacks and limited access to farmland require scientists to participate in extensive R & D.

The organization has partnered with members of the industry to focus on strengthening and using the unique system. In conjunction with the Government Grants Foundation and various self-governing communities, significant associations will improve funding to support R & D and new product improvement attempts for biotechnology funding.

U.S. biotechnology market dominated North America region in 2017 and will continue to project similar trend with +11.1% CAGR during analysis timeframe.

Ask for sample copy of this report at:

https://healthcareintelligencemarkets.com/request_sample.php?id=128077

Top key player profiled in this report:Agilent Technologies, BioGen Medical Instruments, Danaher, F. Hoffmann-La Roche, Abbott Laboratories Illumina, Merck, PerkinElmer, Qiagen and Thermo Fisher Scientific, Amgen, Bio-Rad Laboratories.

The analysis further includes a thorough description based on the dominant competitors that illuminate plant location, capacity, technology development, price structure, value chain, manufacturing methodology, sales / distribution network, raw materials and import and export activities. It also reveals participants financial stability and provides a detailed assessment of their revenue model, sales volume, profit margin and annual growth rate.

Get Expected Discount on this report:https://healthcareintelligencemarkets.com/ask_for_discount.php?id=128077

Today, North America leads the market for Biotechnology, followed by Europe due to the potential of Biotechnology. Emerging economies in Asia Pacific, Latin America, the Middle East and Africa are also expected to grow rapidly in these developing countries as the need for Biotechnology grows.

Technology Outlook (Revenue, USD Billion; 2014 2025)

DNA Sequencing

Nanobiotechnology

Tissue engineering and Regeneration

Fermentation

Cell Based Assay

PCR Technology

Chromatography Market

Others

Application Outlook (Revenue, USD Billion; 2014 2025)

Health

Food & Agriculture

Natural Resources & Environment

Industrial Processing

Bioinformatics

Others

Major factors covered in the report:

Enquiry before buying: https://healthcareintelligencemarkets.com/enquiry_before_buying.php?id=128077

About Us:

At HealthCare Intelligence Markets

Contact Us:

Address: 90, State Office Center,

90, State Street Suite 700,

Albany, NY 12207

Email: sales@healthcareintelligencemarkets.com

Web: http://www.healthcareintelligencemarkets.com

Phone: +1 (888) 616-2766

Read this article:
Astonishing Growth in Biotechnology Market 2019: Insights of the Industry & Rising Demand by Top Companies like Agilent Technologies, BioGen...

The market study on the global Biotechnology Reagent market will encompass the entire ecosystem of the industry, covering five major regions namely North America, Europe, Asia Pacific, Latin America and Middle East & Africa, and the major countries falling under those regions. The study will feature estimates in terms of sales revenue and consumption from 2019 to 2025, at the global level and across the major regions mentioned above. The study has been created using a unique research methodology specifically designed for this market.

(Halloween Special Discount Offer for Limited Period)Add this report toCART and Use Coupon Code HALLOWEEN40 to avail 40% Instant Discounthttps://inforgrowth.com/report/5610186/biotechnology-reagent-market

Quantitative information includes Biotechnology Reagent Market estimates & forecast for a upcoming years, at the global level, split across the key segments covered under the scope of the study, and the major regions and countries. Sales revenue and consumption estimates, year-on-year growth analysis, price estimation and trend analysis, etc. will be a part of quantitative information for the mentioned segments and regions/countries. Qualitative information will discuss the key factors driving the restraining the growth of the market, and the possible growth opportunities of the market, regulatory scenario, value chain & supply chain analysis, export & import analysis, attractive investment proposition, and Porters 5 Forces analysis among others will be a part of qualitative information. Further, justification for the estimates for each segments, and regions will also be provided in qualitative form.

Request a Sample of Biotechnology Reagent Market Research Report and Analysis of Key Players at https://inforgrowth.com/sample-request/5610186/biotechnology-reagent-market

Major players profiled in the report are Abbott Laboratories, Agilent Technologies, Beckman Coulter, BD Medical, Roche Diagnostics, Thermo Fisher Scientific, Merck Millipore, GE Healthcare, Perkinelmer, Tosoh Corporation, Siemens Healthcare, Biomerieux, Sigma Aldrich, Lonza Group, Life Technologies, Quality Biological, Bio-Rad Laboratories, Hoefer.

On the basis of products, report split into, Biotechnology Reagent.

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including Protein Synthesis & Purification, Gene Expression, DNA & RNA Analysis, Drug Testing, Other.

The study will also feature the key companies operating in the industry, their product/business portfolio, market share, financial status, regional share, segment revenue, SWOT analysis, key strategies including mergers & acquisitions, product developments, joint ventures & partnerships an expansions among others, and their latest news as well. The study will also provide a list of emerging players in the Biotechnology Reagent market.

The global Biotechnology Reagent market is bifurcated on the basis of types and on the basis of distribution channel.

Based on regions, the market is classified into North America, Europe, Asia Pacific, Middle East & Africa and Latin America. The study will provide detailed qualitative and quantitative information on the above mentioned segments for every region and country covered under the scope of the study.

Furthermore, this study will help our clients solve the following issues:

This study will address some of the most critical questions which are listed below:

Ask Your Queries or Requirements at https://inforgrowth.com/enquiry/5610186/biotechnology-reagent-market

About InForGrowth:

We are a market-intelligence company formed with the objective of providing clients access to the most relevant and accurate research content for their growth needs. At InForGrowth, we understand Research requirements and help a client in taking informed business critical decisions. Given the complexities and interdependencies of market-intelligence, there is always more than one source to explore and arrive at the right answer. Through our smart search feature and our reliable & trusted publishing partners, we are paving way for a more simplified and relevant research.

Contact:Mr. RohanEmail:[emailprotected] US: +1-909-329-2808 UK: +44-203-743-1890

Continued here:
News Live 2019: Global Biotechnology Reagents Market Rise to High Globally In Next Five Years - Maxi Wire

How far can we go with DNA? The scientific community does not yet have the answer, as the potential of this molecule seems infinite. But to study the possibilities offered in this field, laboratories must still have enough material for researchers to continue their work.

However, for the past forty years, DNA has been manufactured by chemical synthesis. A particularly long and costly process, with an error rate that increases as the sequence lengthens.

In this context, researchers are looking to develop alternatives to synthesize DNA more easily, with more convincing results. Among the solutions considered, one that particularly appealed to the scientific community: enzymatic synthesis. This process, which is faster and more efficient, and for which it is no longer necessary to be a chemist, is now used for the production of medicines, perfumes, cosmetics and biofuels.

The synthetic DNA market is estimated at $1.5 billion, with a growth of 10% per year. The French start-up DNA Script is developing a printer based on genetically modified enzymes to generate a personalized DNA sequence in a few hours. To make synthetic DNA a lever for predictive medicine, but not only, the company raised 11 million in September 2017. And also, an additional 35 million in May.

Founded in 2014 by Thomas Ybert, Sylvain Gariel and Xavier Godron, DNA Script has developed a printer capable of synthesizing high-quality DNA to foster innovation in science and technology. Through this technology, DNA Script intends to give a second wind to the writing of genetic codes.

The new process developed by the company makes it possible to produce better quality and longer DNA molecules. This process is donde in a much shorter time frame than usual production methods. And provides an opportunity for researchers in molecular biology to accelerate their experiments to achieve faster results.

These advances should eventually make it possible to develop new therapeutic products, such as medicines or vaccines. But also to move towards more ecological production of chemicals or to propose a new way of storing data.

DNA Scripts printer could even take on a new dimension with Crispr-Cas9. A genome transformation technique that allows DNA modification by targeting a gene with unparalleled accuracy. To understand better, FrenchWeb went to meet Xavier Godron and Sylvain Gariel. Two of the three founders of the French start-up, in their laboratory at the Kremlin-Bictre, south of Paris.

__

(Featured Image bymadartzgraphics)

First published infrenchweb, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. B2I assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. B2I is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Read the original here:
How synthetic DNA is revolutionizing research in biotechnology - Born2Invest

The French Plant Biotechnology Association (AFBV in French) wants to categorize each published plant. AFBV wants to do this according to the genetic modifications made to their genetic heritage. And not according to the technology used to obtain them, as is currently the case in Europe under Directive 2001/18.

According to the Court of Justice of the European Union (decision of 25 July 2018), plants created through mutagenesis are comparable to genetically modified plants. But only if the technique used existed before the publication of Directive 2001/18 on the deliberate release into the environment of genetically modified organisms. This is why genomic publishing is one of these technologies.

In other words, the decision of the European Court of Justice makes no distinction between the different genetic modifications made to plant genomes. The hazardous insertion, in the genome of a plant, of a gene of another species, is not comparable to genomic editing.

Genome editing consists of simply and precisely modifying the site of the genome of these same plants. Moreover, the decision of the Court of Justice does not take into account the evolution of the technologies used.

If the European Union does not quickly adopt appropriate regulations for these precision biotechnologies, our crops will be in danger. Also, the EUs food security will come under threat. And the competitiveness of European agriculture will suffer a serious handicap, said Georges Freyssinet, President of the Association franaise des biotechnologies vgtales (AFBV).

As farmers have fewer and fewer products available to effectively treat their crops, orchards and vegetables, they need new varieties of plants. Ones that can naturally defend themselves against predators (insects) and parasites (fungi). For example, by emitting volatile repellent substances.

Rapeseed cultivation is already at risk. Cereal growers no longer have the means to effectively eradicate flea beetles. Because the authorities banned the use of neonicotinoids.

At the same time, however, the European Union imports products treated with substances banned on its territory.

The AFBV wants to enable European research to continue its plant breeding work. In this regard, the AFBV and other European associations propose to categorize genetically modified plants according to the nature of the transformation carried out on their genome.

And then, to prepare a dossier to confirm on a case-by-case basis, before release or marketing, whether or not the published plants are excluded from Directive 2001/18.

According to the genetic modifications made, the AFBV distinguishes four categories of published plants.

The first category includes plants with a known allele. The one present in the genetic heritage of the species to which they belong. This first category of plants is different from the second. That would include plants published according to a known allele model but present in the plant kingdom in general.

If the introduced allele is new, of the type obtained through mutagenesis, then the plants would be in category 3. And if the insertion concerns several genes of a plant of the same species, then the published plants would constitute the fourth category.

The AFBV will submit this proposal to the European Commission for an update of the European Directive 2001/18 on GMOs during its next mandate. The directive must also cover imported products.

As the European market is no longer profitable, countries that export these commodities in the near future could deliberately turn away from them by no longer producing the authorized commodities.

__

(Featured Image byStephen Radford via Unsplash)

First published inwikiagri, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

See the original post here:
The AFBV moves ahead with new categorization for plants - Born2Invest

DUBLIN, Oct. 25, 2019 /PRNewswire/ -- The "Improving Processes and CAPA (Corrective and Preventative Action)" conference has been added to ResearchAndMarkets.com's offering.

The course has been specifically designed for the Pharma, Biotechnology, Devices and Veterinary industries and particularly if you are involved in process improvement, corrective and preventative action, problem solving and managing inspections and documenting how to deal with these.

This meeting will cover CAPA methodology and documentation, diagnosing process improvement, developing options for process improvement and CAPA and planning and implementation in practice of improvements and CAPA

With this one-day course you will learn how to use the most efficient processes and ensure compliance with Corrective and Preventative Action (CAPA) within the pharmaceutical, medical device and animal health industries.

Regulatory inspectors are increasing reviewing responses to findings dealt with by the CAPA approach and process improvement. It is highly likely that organisations who have already been inspected will be assessed at their next inspection in terms of whether the corrective and preventative actions have been implemented. If previous major findings have not been addressed then a critical finding may be given. This course will be ideal for you to learn how to improve industry procedures and processes and how to implement and document an effective CAPA quality system.

Why you should attend

It is highly likely that organisations who have already been inspected will be assessed at their next inspection in terms of whether the corrective and preventative actions have been implemented - has the organisation done what they said they would? If previous major findings have not been addressed then a critical finding may be given. This couse will be ideal for you to learn how to improve industry procedures and processes and how to implement and document an effective CAPA quality system.

Topics to be covered include:

Agenda:

Why is CAPA important?

CAPA Methodology and Documentation

Diagnosing Process Improvement

Developing Options for Process Improvement and CAPA

Planning and Implementation in Practice of Improvements and CAPA

Final Discussion

For more information about this conference visit https://www.researchandmarkets.com/r/qcawr8

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read the rest here:
One Day Improving Processes and CAPA (Corrective and Preventative Action) Course Designed for the Pharma, Biotechnology, Devices and Veterinary...

Swiss biotech company BioVersys AG has received a 8m grant by US-based non-profit organisation CARB-Xto develop novel anti-virulence antibiotics to treat severe bacterial infections.

Privately-owned BioVersys AG, headquartered in Basel, is focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications to fight antimicrobial resistance (AMR) and targeted microbiome modulation. The most advanced R&D programmes are in preclinical development for nosocomial infections (hospital infections), and tuberculosis in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille. In 2020, BioVersys plans to launch its first Phase I clinical trials, for its two leading programmes, which focus on Acinetobacter baumannii and Mycobacterium tuberculosis (TB) infections. The TB programme runs within the recently started TRIC-TB consortium and is financed with a total 6.9m under the umbrella of the new European AMR accelerator initiated by the Innovative Medicines Initiative (IMI).

This new CARB-X grant will help to further advance a third asset from the companys R&D pipeline towards clinical stages. It provides the company with non-dilutive funding of 3.5m upfront and up to an extra 4.5m if certain milestones are met. BioVersys will use the money to push forward its BV200 series of molecules that has been developed using the companys TRIC technology (Transcriptional Regulator Inhibitory Compounds). These are not direct acting antibiotics, but rather a new class of molecules, capable of disarming bacteria such as Staphylococcus aureus including MRSA of their harmful virulence factors including toxins, that cause serious skin infections that can spread to muscles, lungs and other body parts. According to the company, they have the potential to be used as stand-alone therapy as well as in combination with antibiotics, thus improving many available antibiotic therapies and supporting stewardship. The most advanced compounds are in Lead Optimisation.

We are delighted that CARB-X recognises the immense potential of BioVersys anti-virulence programme (BV200) through this funding award, said Marc Gitzinger, CEO and Co-Founder of BioVersys. The diversity in the challenge of AMR diseases requires us to broaden our approach beyond classical antibiotics, and further R&D investment in novel paradigm shifting approaches such as anti-virulence is vitally important.

Molecules of the BV200 class inhibit the transcriptional regulator AgrA which controls the production of harmful virulence factors including -toxin, phenol-soluble-modulin (PSM) and Panton-Valentine leukocidin (PVL) toxins that are directly linked to the severity of S. aureus-mediated skin and skin structure infections (SSSIs) and pneumonia. By preventing the expression of the toxins, the molecules have the potential to reduce tissue damage, disease progression and, consequently, reduce infection severity and mortality rates in patients. The BV200 series will initially be developed for skin and skin structure infections (SSSI) and pneumonia caused by S. aureus, including Methicillin-resistant S. aureus (MRSA).

Drug-resistant bacteria represent one of the greatest threats to public health globally. New approaches, like the BioVersys project, are urgently needed to help save lives and to curb the spread of drug-resistant bacteria, said Kevin Outterson, Executive Director of CARB-X, which is based at the Boston University School of Law. This project is in early stages of development but if successful and approved for use in patients, it would represent tremendous progress in the fight against drug resistance, by offering an alternative therapy to traditional antibiotics and also restoring the effectiveness of existing antibiotics.

The new investment adds another European company to the CARB-X portfolio, the worlds largest antibacterial development portfolio. Currently, it includes 30 projects in five countries. Since its inception in 2016, CARB-X has announced 49 awards exceeding US$155m, with the potential of additional funds if project milestones are met, to accelerate the development of antibacterial products. CARB-X is led by Boston University and funding is provided by the Biomedical Advanced Research and Development Authority (BARDA), the Wellcome Trust, Germanys Federal Ministry of Education and Research (BMBF), the UK Department of Health and Social Cares Global Antimicrobial Resistance Innovation Fund (GAMRIF), the Bill & Melinda Gates Foundation, and with in-kind support from National Institute of Allergy and Infectious Diseases (NIAID).

See the original post:
BioVersys receives up to 8m from CARB-X - European Biotechnology